Skip to content

Skin Rejuvenation With Topical Extract and Other Nutraceuticals

Skin Rejuvenation Using Topical Hemp-based Extract and Other Nutraceuticals

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05734703
Enrollment
25
Registered
2023-02-21
Start date
2023-03-01
Completion date
2023-06-01
Last updated
2023-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lines Skin, Spot Pigmented, Wrinkle

Keywords

hemp extract, caffeine, resveratrol, thyme

Brief summary

Hemp extract has been shown in several pre-clinical and clinical studies to have anti-aging effects on the skin through anti-oxidant and anti-inflammatory effects, in addition resveratrol, thyme and caffeine have been shown to have anti-aging effects related to fibrillar collagen production and extracellular matrix production in the dermis. A combination of these four ingredients will be used in a vehicle of fermented medium chain triglyceride oil and skin shave biopsies will be taken before and after 90 days use of the topical to look for objective evidence of anti-aging effects in the dermis and epidermis.

Detailed description

The study is a case series of 25 adults over age 50 identified through social media outreach in the Tampa Bay area. Each subject will be given a topical serum and advised to apply it once daily to the specific two by two inch area of skin under study (forearm or back of the neck). The serum will be comprised of hemp-extract, resveratrol, caffeine, thyme oil and fermented medium chain triglyceride as a vehicle. The skin anti-aging serum is expected to contain hemp-extract 5%, caffeine 2%, Thyme essential oil 2% and resveratrol 0.5%. The subjects will use the test formulation for 90 days. The subjects will jhave shaved skin biopsies taken on either the forearm or back of the neck. The biopsies will be done on day zero and on day 90. None of the subjects are currently using anti-aging therapies. No other anti-aging therapy will be used during the 90 days of the research. The subjects will be advised to apply a thin layer of the serum once each night at bedtime. To the area of skin under study (forearm or back of the neck). The one-ounce bottle of serum is expected to last for the entire 90 days of the study. The subjects will be reminded each day via text messaging to use the product and each subject will be required to text back that the daily treatment has been applied. The 'before and after' shaved biopsies will be independently evaluated by Dr. Michael Morgan, board certified Dermatopathologist at KorPath, Inc. He will perform hematoxylin and eosin (H&E) staining, for histological analysis for morphology of the dermis and epidermis and histochemical staining for collagen and matrix analysis. The subjects will be independently clinically evaluated by Dr. Kathy Anderson, board certified Dermatologist. She will determine before and after skin wrinkling scores using standard recognized metrics. Each subject will have a diary app added to their smart phones to document daily use and potential adverse effects. The results will be statistically evaluated with a standard for comparison. Study results with a p-value less than 0.05 will be determined to be statistically significant and the result will be evaluated for efficiency compared to generally recognized therapies . The study will be prepared in standard fashion and submitted to recognized peer-review medical journals.

Interventions

DRUGNutraceutical Topical

Once daily application of the topical nutraceutical to two by two inch area of skin for 90 days.

Sponsors

Medical Life Care Planners, LLC
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

One group of 25 adults aged 50 or over.

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age 50 or over * Glogau Wrinkle Severity Scale of either 3 or 4 on the area to be biopsied. * Not on current anti-aging therapies used as an ingredient in the study topical.

Exclusion criteria

* Under age 50 * Glogau Wrinkle Severity Scale of either 1 or 2 on the area to be biopsied. * Currently using anti-aging therapies used as an ingredient in the study topical. * Contraindication to performing skin shave biopsies in the area to be biopsied.

Design outcomes

Primary

MeasureTime frameDescription
dermal-epidermal juncton flattening90 daysHistologic appearance of dermal-epidermal flattening on 'before' and 'after' skin biopsies.
elastic fiber attenuation90 daysHistologic appearance of elastic fiber attenuation in the dermis on 'before' and 'after' skin biopsies.
denisty of collagen fiber network90 daysHistologic appearance of the density of the collagen fibers on 'before' and 'after' skin biopsies.

Secondary

MeasureTime frameDescription
Glogau System: Wrinkle Severity Ranking90 daysGlogau System: Wrinkle Severity Ranking score from 1-4 on 'before' and 'after' dermatologist physical examination of treated area
Modified Fitzpatrick Wrinkle Scale90 daysModified Fitzpatrick Wrinkle Scale from class 0-2.5 on 'before' and 'after' dermatologist physical examination of treated area

Countries

United States

Contacts

Primary ContactGregory L Smith, MD
drsmith@nex-therapeutics.com7278517972
Backup ContactKathy Anderson, MD
kathya@gmail.com8137873180

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026